Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > PH2 Liver transient elevatisame as you guessed it nasaids...

<< Previous

Bullboard Posts

Next >>

Comment by IrishCanuckon Aug 08, 2021 9:07pm

298 Views

Post# 33670265

RE:RE:RE:PH2 Liver transient elevatisame as you guessed it nasaids...

I thought they were already planning to fast-track 352 and it was supposed to be Q1, but now we won't know prioritization for a while or if any delays occur. If they can keep up with the animal toxicology I don't see why they wouldn't try doing that. But we'll see...

WalkOverTheStrt wrote:

IrishCanuck -solid points and hopefully Candad Health and FDA see it the same way.
Do you think Antibe will try to accelerate 352 to humans (right now 2022 no qtr date) to help support the stock price and strive for early human results in 2022?
Are you expecting data analysis to be completed by Antibe in the coming weeks or are you expecting multiple months?